STAT
FEBRUARY 14, 2024
Last week, the Washington Post published an op-ed by former CDC Director Tom Frieden titled, “It’s the world’s leading killer. Make it the focus of the next breakthrough.” Frieden writes, “Hypertension, the ‘silent killer,’ is the deadliest but most neglected and widespread pandemic of our time, killing more than 10 million people a year worldwide.
PharmaVoice
FEBRUARY 14, 2024
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
FEBRUARY 14, 2024
Public health messages have told us for decades that if you smoke, you should quit. And if you don’t smoke, don’t start. But a new study suggests smoking may be even worse than we thought. The study , published Wednesday in Nature, underscores the importance of never lighting up that first cigarette, based on its conclusion that smoking has much longer harmful effects on immune responses than previously understood.
The Pharmacist
FEBRUARY 14, 2024
The General Pharmaceutical Council (GPhC) has announced the appointment of five new members to its governing council, including a community pharmacist. Adeyemi (Ade) Williams, superintendent pharmacist and director of M J Williams Pharmacy, and lead pharmacist at the Bedminster Pharmacy, Bristol, will begin his term on 1 April 2024. Joining him will be Professor Dianne […] The post GPhC announces five new council members appeared first on The Pharmacist.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
FEBRUARY 14, 2024
The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key medicines at hospitals and other facilities across the country. The agency will explore how these companies — which are responsible for brokering and distributing countless medicines — might misuse their market power to influence pricing and availability.
pharmaphorum
FEBRUARY 14, 2024
Discover how artificial intelligence (AI) is revolutionising the drug development process and transforming the way FDA-approved drugs are produced, ensuring compliance and optimising the supply chain. Learn more about the future of AI in pharmaceuticals.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharma Times
FEBRUARY 14, 2024
The aggressive type of cancer accounts for 13% of all lung cancer cases worldwide
STAT
FEBRUARY 14, 2024
It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira , used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders.
BioPharma Dive
FEBRUARY 14, 2024
Latigo Biotherapeutics has raised $135 million to develop drugs that block NaV1.8, a target shared by a Vertex therapy that just succeeded in Phase 3 testing.
STAT
FEBRUARY 14, 2024
After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals. The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
BioPharma Dive
FEBRUARY 14, 2024
The company and partner Biogen say signs from payers and doctors suggest the launch of Zurzuvae, the first oral therapy for PPD, is off to a good start.
STAT
FEBRUARY 14, 2024
A leaked version of a proposed agreement between India and the European Free Trade Association is causing alarm among civil society and patient advocacy groups over concerns the deal would delay access to affordable generic versions of newer, lifesavings medicines for several years. The language in a draft agreement, which is expected to be concluded by April, suggests changes would have to be made to India’s patent and regulatory laws.
pharmaphorum
FEBRUARY 14, 2024
Ipsen has won FDA approval for first-line use of its pancreatic cancer therapy Onivyde, saying it is now part of a potential new “standard-of-care” for patients
STAT
FEBRUARY 14, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! And it’s Meghana again. Today, we discuss how Biogen’s missed the mark with Leqembi, but how it’s also not exactly a surprise. We see a new startup emerge that aims to compete with Vertex Pharmaceuticals, and learn of Phase 1 results for Replicate’s srRNA rabies vaccine.
Outsourcing Pharma
FEBRUARY 14, 2024
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
STAT
FEBRUARY 14, 2024
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Express Pharma
FEBRUARY 14, 2024
With over 100 International and Domestic Exhibitors, Vitafoods India promises to be an unparalleled platform for the nutraceutical industry Informa Markets commenced the 2nd edition of Vitafoods India at the Jio World Convention Center, Mumbai. The three-day event, a dedicated expo showcasing the fast-transforming Indian nutraceutical market, witnessed significant participation with over 100 domestic and international exhibiting companies taking center stage.
STAT
FEBRUARY 14, 2024
WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts. Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection.
Express Pharma
FEBRUARY 14, 2024
MSF has appealed to the Prime Minister to continue rightfully rejecting the inclusion of intellectual property provisions in the EFTA negotiations Following news that India and the European Free Trade Association (EFTA) – which comprises Iceland, Liechtenstein, Norway, and Switzerland – are close to finalising a trade deal, Doctors Without Borders/Médecins Sans Frontières (MSF), Public Eye, and Delhi Network of Positive People warned that if the final text retains the currently-included harmful
pharmaphorum
FEBRUARY 14, 2024
Eicos Sciences' Aurlumyn has become the first FDA-approved drug treatment to prevent amputations in cases of severe frostbite
European Pharmaceutical Review
FEBRUARY 14, 2024
Gilead Sciences has agreed to acquire CymaBay Therapeutics for a total equity value of $4.3 billion. Gilead confirmed that CymaBay’s lead product candidate seladelpar has a best-in-disease profile for second-line primary biliary cholangitis (PBC). This is based on data from the Phase III RESPONSE trial. The company shared that seladelpar is an oral, selective peroxisomeproliferator-activated receptor delta (PPARδ) agonist.
Pharma Times
FEBRUARY 14, 2024
The report includes five recommendations for the government to address these issues
European Pharmaceutical Review
FEBRUARY 14, 2024
The development of drug products containing live anaerobic bacterial strains as the active pharmaceutical ingredient and where potency and shelf-life is typically associated with viable cell quantification, poses unique challenges when compared to both small and large molecule development therapeutics. It is the uniqueness of the strain and perceived inter-cellular variations (sub-populations) resulting from high viable cell densities during growth (fermentation) and the subsequent harvest and d
World Pharma News
FEBRUARY 14, 2024
A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk. Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease.
European Pharmaceutical Review
FEBRUARY 14, 2024
A report by Allied Market Research predicts that the global pharmaceutical suspension market will reach $83.8 billion by 2032. Having valued $55.5 billion in 2022, the research expected that the market will reach a CAGR of 4.2 percent between 2023 and 2032. Factors driving the global pharmaceutical suspension market One of the main factors anticipated to propel the growth of the pharmaceutical suspension market is the availability of generic pharmaceutical suspensions, the research asserted.
BioPharma Dive
FEBRUARY 14, 2024
The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.
Pharmaceutical Technology
FEBRUARY 14, 2024
A bipartisan group of lawmakers is seeking an investigation and sanctions against WuXi given alleged connections to the Chinese military.
Drug Channels
FEBRUARY 14, 2024
It's Valentine’s Day—and commercial plan sponsors remain smitten with copay accumulators and maximizers. Our latest update finds that as of late 2023, about half of commercial lives were in plans that utilize a copay accumulator and/or a maximizer. These programs’ growth continues to divert the value of a manufacturer’s copay support payments away from patients and toward plans and PBMs.
Pharmafile
FEBRUARY 14, 2024
Ipsen has announced that the US Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Onivyde (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (Nalirifox) as a first line treatment for adult patients with metastatic pancreatic adenocarcinoma (mPDAC). This approval is the second for an Onivyde regimen in mPDAC, following […] The post FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma treatment appeared first on
The Guardian - Pharmaceutical Industry
FEBRUARY 14, 2024
Years of wrangling have ended in stalemate as campaigners question fairness of system for low and middle-income countries The World Trade Organization has failed to reach an agreement to waive intellectual property rights on Covid-19 tests and treatments for poorer countries. Members of the Trade-Related Aspects of Intellectual Property Rights (Trips) council said it could not reach consensus after years of discussion, despite the “considerable efforts” of members.
BioPharma Dive
FEBRUARY 14, 2024
The biotech is planning to dissolve less than four years after launching with plans to license drugs and market them in China and other Asian countries.
Pharmaceutical Business Review
FEBRUARY 14, 2024
Ally Bridge Group led the funding round, which saw contributions from healthcare focused and mutual fund institutional investors. New investors comprised Nextech Invest, funds and accounts advised by T. Rowe Price Associates, Janus Henderson Investors, RA Capital Management and Medicxi among others. The company also received investments from current investors Lilly Asia Ventures and LYFE Capital.
Pharmafile
FEBRUARY 14, 2024
Domainex has announced that it has opened a new Biology Centre of Excellence at the Unity Campus at Pampisford, Cambridge, UK, in order to further support collaborations with pharmaceutical and biotechnology companies, patient foundations and academic institutions. The facility had a grand opening on 7 February 2024, officiated by Mrs Julie Spence OBE CStJ QPM, […] The post Domainex opens new Biology Centre of Excellence in Cambridge, UK appeared first on Pharmafile.
pharmaphorum
FEBRUARY 14, 2024
Venture capital group Earlybird has launched its second health fund with $185 million to fund companies in the health technology area
Pharmacy Joe
FEBRUARY 14, 2024
In this episode, I’ll discuss the effect of unnecessary long-term continuation of newly initiated stress ulcer prophylaxis in the ICU on morbidity and mortality after hospital discharge. Episode 896: Just How Bad Are PPIs When Continued Post-ICU Stay Without Indication? Subscribe on iTunes , Android , or Stitcher ICU patients are routinely started on proton pump inhibitor therapy for the purpose of stress ulcer prophylaxis.
Expert insights. Personalized for you.
337 
Let's personalize your content